Owc Pharmaceutical Research Corp (OWCP) 0.0324 $OWCP
OWC Pharma (OWCP) Advances Study & Expands into Consulting
ACCESSWIRE - Tue May 03, 8:25AM CDT
SEATTLE, WA / ACCESSWIRE / May 3, 2016 / The medical cannabis industry has been a hot topic within the investment community over the past month after GW Pharmaceuticals plc (NASDAQ: GWPH) reported positive results in the first of two clinical trials evaluating Epidiolex for the treatment of rare forms of epilepsy. In 120 randomized patients suffering from Dravet syndrome, Epidiolex reduced the number of monthly seizures by 39% compared to 11% for patients receiving placebo.
GWPH: 85.62 (-1.52)
OWC Pharmaceuticals Corp to Present at Israeli Advanced Technology Industry's BioMed Conference
PR Newswire - Tue Apr 26, 7:00AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"
, an Israeli-based developer of cannabinoid-based therapies targeting a variety of different indications, today announced that it was selected to present at the 2016 Israeli Advanced Technology Industries (IATI) BioMed Conference (the "Conference".
OWC Pharmaceutical Comments on Israel's Proposed Medical Cannabis Guidelines
PR Newswire - Tue Apr 12, 7:00AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company", an Israeli-based developer of cannabinoid-based therapies targeting a variety of different indications, today commented on the proposed change to Israel's medical cannabis regulations. The second country to approve marijuana for medical use (in 2003), Israel is also a leader in cannabis research, making it a popular location for companies like OWC. Dr. Yehuda Baruch, OWC's Director of Research and Regulation, was the first director of the Israeli MMJ program from 2003 - 2013.
OWC Pharmaceutical Research Advances Its Multiple Myeloma Study to Animals
PR Newswire - Tue Mar 29, 7:00AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company", an Israeli-based developer of cannabinoid-based therapies targeting a variety of different indications, today announced that it has completed in-vitro testing on its formulation for multiple myeloma and is preparing to begin pre-clinical safety and efficacy studies on mice.
OWC Looks to Bring Pharma-Grade Cannabis Therapeutics to Market
ACCESSWIRE - Tue Mar 15, 8:24AM CDT
SEATTLE, WA / ACCESSWIRE / March 15, 2016 / There are many different companies active in the medical marijuana industry, but few of them are conducting clinical research trials in accord with the Helsinki Committee Institutional Review Board protocols. Most investors are familiar with GW Pharmaceuticals plc (NASDAQ: GWPH) and its Sativex® cannabinoid medicine for the treatment of multiple sclerosis symptoms and cancer pain indications, but OWC Pharmaceutical Research Corp. (OTCQB: OWCP) is a lesser known company operating in the burgeoning industry.
CARA: 5.26 (-0.11), GWPH: 85.62 (-1.52)
Jeffrey Friedland Joins OWC Pharmaceutical Research's Advisory Board
PR Newswire - Tue Mar 15, 7:08AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company", an Israeli-based developer of cannabinoid-based therapies targeting a variety of different indications, today announced that Jeffrey Friedland has joined the Company's Advisory Board. In addition to advising OWC on its business development efforts, Mr. Friedland will serve as the Company's U.S. representative.
OWC Pharmaceutical Research Corp Completes Formulation of Cannabinoid-Infused Topical Cream
PR Newswire - Wed Mar 09, 7:32AM CST
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company", an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that it has completed development of a topical cream compound designed to ensure the effective delivery and dosage of its proprietary cannabinoid formulations. The cream was developed through a strategic alliance with Emilia Cosmetics Ltd., one of Israel's largest private label cosmetics manufacturers.
OWC Pharmaceutical Research Announces $750K Equity Purchase Agreement With Kodiak Capital Group
PR Newswire - Mon Jan 11, 7:00AM CST
OWC Pharmaceutical Research Corp. (OTC: OWCP), an Israel-based pharmaceutical research company dedicated to the development of cannabinoid treatments, products and delivery technologies, today announced that it has entered into a $750,000 equity purchase agreement ("Agreement" with Kodiak Capital Group, LLC ("Kodiak".
One World Cannabis to Offer New Alternative Treatment for Chronic Pain in Light Of FDA's NSAIDs Warning
PR Newswire - Wed Jul 15, 7:17AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), an Israeli-based developer of cannabinoid-based therapies targeting a variety of different indications, is offering new and alternative hope to patients diagnosed with chronic pain. The company's wholly owned subsidiary, One World Cannabis Ltd., has already filed two provisional patent applications with the USPTO related to the development of two unique formulations that include cannabis extracts and a new delivery system to treat fibromyalgia and migraines, and has begun researching and developing new cannabis-based therapies to help alleviate the suffering of patients experiencing enduring pain.
OWC Pharmaceutical Research Announces the Promising Results of Phase Lab Testing for Multiple Myeloma
PR Newswire - Wed Jun 17, 7:00AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), today announced that its wholly owned subsidiary, One World Cannabis Ltd. ("the Company", an Israel-based developer of cannabinoid-based therapies targeting a variety of different indications, is proud to announce it has received the first basic science study (lab) results on the effect of several combination of Cannabidiol (CBD) and tetrahydrocannabinol (THC) on multiple myeloma cell line RPMI8226.
One World Cannabis Implements Regulatory - Patient-Care Services for New York Applications in Medical Cannabis Program
PR Newswire - Mon May 18, 7:00AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), an Israel-based developer of cannabinoid-based therapies targeting a variety of different indications, announced that its wholly-owned subsidiary, One World Cannabis Ltd. ("the Company", is implementing regulation and patient-care consultancy services in New York to further advance the application and registration of medical cannabis business licenses within the existing Medical Cannabis Program.
OWC Pharmaceutical Research and Sheba Medical Center to Extend Contract for Fibromyalgia Clinical Trials
PR Newswire - Wed May 13, 7:00AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), through its wholly-owned Israel-based Israel subsidiary, One World Cannabis Ltd. (the "Company" developer of cannabinoid-based therapies targeting a variety of different medical indications, today announced that it has extended its contract with Sheba Academic Medical Center to further conduct clinical trials on fibromyalgia to help to advance better treat patients through the use of medical cannabis.
OWC Partners With G.C. Group to Develop Cannabinoid-Based Formulations and Delivery Methods for Several Medical Indications
PR Newswire - Wed Apr 22, 7:00AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), developer of cannabinoid-based therapies and consulting services to governments, today announced that its wholly owned subsidiary, One World Cannabis Ltd. ("the Company", has entered into agreement with G.C. Group to develop new formulations and delivery methods targeting several medical indications.
One World Cannabis Moves Forward to Test Human Cells in its Multiple Myeloma Study
PR Newswire - Wed Apr 15, 8:39AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), today announced that its wholly owned subsidiary, One World Cannabis Ltd. ("the Company", an Israel-based developer of cannabinoid-based therapies targeting a variety of different indications, is proud to announce that after receiving preliminary results on the effect of several combinations of cannabinoil (CBD) and tetrahydrocannabidoil (THC) on multiple myeloma cells, its basic science study continues with multiple myeloma human cells.
One World Cannabis Files 6th Provisional Patent Application With USPTO
PR Newswire - Tue Mar 24, 7:30AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), an Israel-based developer of cannabinoid-based therapies targeting a variety of different indications, today announced that its wholly owned subsidiary, One World Cannabis Ltd. ("the Company", had their sixth provisional application filled with the USPTO.
One World Cannabis Signed a Collaboration Agreement with Sheba Academic Medical Center
PR Newswire - Wed Mar 11, 8:00AM CDT
OWC Pharmaceutical Research Corp.'s (OTCQB: OWCP) wholly owned subsidiary One World Cannabis Ltd. ("the Company", signed a collaboration agreement with Sheba Academic Medical Center, the largest hospital in Israel and in the Middle East.
OWC Pharma (OWCP) Advances Study & Expands into Consulting
ACCESSWIRE - Tue May 03, 8:25AM CDT
SEATTLE, WA / ACCESSWIRE / May 3, 2016 / The medical cannabis industry has been a hot topic within the investment community over the past month after GW Pharmaceuticals plc (NASDAQ: GWPH) reported positive results in the first of two clinical trials evaluating Epidiolex for the treatment of rare forms of epilepsy. In 120 randomized patients suffering from Dravet syndrome, Epidiolex reduced the number of monthly seizures by 39% compared to 11% for patients receiving placebo.
GWPH: 85.62 (-1.52)
OWC Pharmaceuticals Corp to Present at Israeli Advanced Technology Industry's BioMed Conference
PR Newswire - Tue Apr 26, 7:00AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"
, an Israeli-based developer of cannabinoid-based therapies targeting a variety of different indications, today announced that it was selected to present at the 2016 Israeli Advanced Technology Industries (IATI) BioMed Conference (the "Conference". OWC Pharmaceutical Comments on Israel's Proposed Medical Cannabis Guidelines
PR Newswire - Tue Apr 12, 7:00AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"
, an Israeli-based developer of cannabinoid-based therapies targeting a variety of different indications, today commented on the proposed change to Israel's medical cannabis regulations. The second country to approve marijuana for medical use (in 2003), Israel is also a leader in cannabis research, making it a popular location for companies like OWC. Dr. Yehuda Baruch, OWC's Director of Research and Regulation, was the first director of the Israeli MMJ program from 2003 - 2013. OWC Pharmaceutical Research Advances Its Multiple Myeloma Study to Animals
PR Newswire - Tue Mar 29, 7:00AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"
, an Israeli-based developer of cannabinoid-based therapies targeting a variety of different indications, today announced that it has completed in-vitro testing on its formulation for multiple myeloma and is preparing to begin pre-clinical safety and efficacy studies on mice. OWC Looks to Bring Pharma-Grade Cannabis Therapeutics to Market
ACCESSWIRE - Tue Mar 15, 8:24AM CDT
SEATTLE, WA / ACCESSWIRE / March 15, 2016 / There are many different companies active in the medical marijuana industry, but few of them are conducting clinical research trials in accord with the Helsinki Committee Institutional Review Board protocols. Most investors are familiar with GW Pharmaceuticals plc (NASDAQ: GWPH) and its Sativex® cannabinoid medicine for the treatment of multiple sclerosis symptoms and cancer pain indications, but OWC Pharmaceutical Research Corp. (OTCQB: OWCP) is a lesser known company operating in the burgeoning industry.
CARA: 5.26 (-0.11), GWPH: 85.62 (-1.52)
Jeffrey Friedland Joins OWC Pharmaceutical Research's Advisory Board
PR Newswire - Tue Mar 15, 7:08AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"
, an Israeli-based developer of cannabinoid-based therapies targeting a variety of different indications, today announced that Jeffrey Friedland has joined the Company's Advisory Board. In addition to advising OWC on its business development efforts, Mr. Friedland will serve as the Company's U.S. representative. OWC Pharmaceutical Research Corp Completes Formulation of Cannabinoid-Infused Topical Cream
PR Newswire - Wed Mar 09, 7:32AM CST
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"
, an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that it has completed development of a topical cream compound designed to ensure the effective delivery and dosage of its proprietary cannabinoid formulations. The cream was developed through a strategic alliance with Emilia Cosmetics Ltd., one of Israel's largest private label cosmetics manufacturers. OWC Pharmaceutical Research Announces $750K Equity Purchase Agreement With Kodiak Capital Group
PR Newswire - Mon Jan 11, 7:00AM CST
OWC Pharmaceutical Research Corp. (OTC: OWCP), an Israel-based pharmaceutical research company dedicated to the development of cannabinoid treatments, products and delivery technologies, today announced that it has entered into a $750,000 equity purchase agreement ("Agreement"
with Kodiak Capital Group, LLC ("Kodiak". One World Cannabis to Offer New Alternative Treatment for Chronic Pain in Light Of FDA's NSAIDs Warning
PR Newswire - Wed Jul 15, 7:17AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), an Israeli-based developer of cannabinoid-based therapies targeting a variety of different indications, is offering new and alternative hope to patients diagnosed with chronic pain. The company's wholly owned subsidiary, One World Cannabis Ltd., has already filed two provisional patent applications with the USPTO related to the development of two unique formulations that include cannabis extracts and a new delivery system to treat fibromyalgia and migraines, and has begun researching and developing new cannabis-based therapies to help alleviate the suffering of patients experiencing enduring pain.
OWC Pharmaceutical Research Announces the Promising Results of Phase Lab Testing for Multiple Myeloma
PR Newswire - Wed Jun 17, 7:00AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), today announced that its wholly owned subsidiary, One World Cannabis Ltd. ("the Company"
, an Israel-based developer of cannabinoid-based therapies targeting a variety of different indications, is proud to announce it has received the first basic science study (lab) results on the effect of several combination of Cannabidiol (CBD) and tetrahydrocannabinol (THC) on multiple myeloma cell line RPMI8226. One World Cannabis Implements Regulatory - Patient-Care Services for New York Applications in Medical Cannabis Program
PR Newswire - Mon May 18, 7:00AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), an Israel-based developer of cannabinoid-based therapies targeting a variety of different indications, announced that its wholly-owned subsidiary, One World Cannabis Ltd. ("the Company"
, is implementing regulation and patient-care consultancy services in New York to further advance the application and registration of medical cannabis business licenses within the existing Medical Cannabis Program. OWC Pharmaceutical Research and Sheba Medical Center to Extend Contract for Fibromyalgia Clinical Trials
PR Newswire - Wed May 13, 7:00AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), through its wholly-owned Israel-based Israel subsidiary, One World Cannabis Ltd. (the "Company"
developer of cannabinoid-based therapies targeting a variety of different medical indications, today announced that it has extended its contract with Sheba Academic Medical Center to further conduct clinical trials on fibromyalgia to help to advance better treat patients through the use of medical cannabis. OWC Partners With G.C. Group to Develop Cannabinoid-Based Formulations and Delivery Methods for Several Medical Indications
PR Newswire - Wed Apr 22, 7:00AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), developer of cannabinoid-based therapies and consulting services to governments, today announced that its wholly owned subsidiary, One World Cannabis Ltd. ("the Company"
, has entered into agreement with G.C. Group to develop new formulations and delivery methods targeting several medical indications. One World Cannabis Moves Forward to Test Human Cells in its Multiple Myeloma Study
PR Newswire - Wed Apr 15, 8:39AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), today announced that its wholly owned subsidiary, One World Cannabis Ltd. ("the Company"
, an Israel-based developer of cannabinoid-based therapies targeting a variety of different indications, is proud to announce that after receiving preliminary results on the effect of several combinations of cannabinoil (CBD) and tetrahydrocannabidoil (THC) on multiple myeloma cells, its basic science study continues with multiple myeloma human cells. One World Cannabis Files 6th Provisional Patent Application With USPTO
PR Newswire - Tue Mar 24, 7:30AM CDT
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), an Israel-based developer of cannabinoid-based therapies targeting a variety of different indications, today announced that its wholly owned subsidiary, One World Cannabis Ltd. ("the Company"
, had their sixth provisional application filled with the USPTO. One World Cannabis Signed a Collaboration Agreement with Sheba Academic Medical Center
PR Newswire - Wed Mar 11, 8:00AM CDT
OWC Pharmaceutical Research Corp.'s (OTCQB: OWCP) wholly owned subsidiary One World Cannabis Ltd. ("the Company"
, signed a collaboration agreement with Sheba Academic Medical Center, the largest hospital in Israel and in the Middle East. 
